Three Decades of Microchip Data
Companion animal microchipping began in the mid-1990s and has since become standard practice in veterinary medicine. Tens of millions of dogs worldwide carry implanted microchips, with mandatory microchipping laws in place in the UK, Australia, and several other countries. This massive implant population over three decades provides an unusually robust safety dataset compared to most veterinary interventions.
The technology itself is straightforward: a passive radio-frequency identification (RFID) transponder encased in biocompatible glass, approximately 12 mm long and 2 mm in diameter, injected subcutaneously between the shoulder blades. The device contains no battery, no moving parts, and no active electronics — it is activated only when scanned by an external reader.
Lord et al. (2009) studied microchip identification in shelter settings and found that microchipped dogs were returned to their owners at a rate of 52.2% compared to 21.9% for non-microchipped dogs. This reunion rate benefit is the primary justification for the procedure and is not seriously disputed.
Adverse Event Profile
The documented adverse events associated with microchip implantation in dogs include:
Migration: The most common adverse event. Microchips can migrate from the interscapular implantation site to other locations — most commonly along the dorsal midline or laterally along the thoracic wall. Migration rates vary by study from 1-6% and generally have no clinical significance beyond potentially making the chip harder to locate during scanning.
Implantation site reactions: Transient swelling, inflammation, or pain at the injection site occurs in a small percentage of dogs. These reactions are typically self-limiting and resolve within 48-72 hours. Abscess formation is documented but rare.
Tumor formation: This is the adverse event that generates the most owner concern. Vascellari et al. (2003) documented fibrosarcomas at presumed injection sites in dogs, though establishing a direct causal link between the microchip and tumor formation is challenging. The reported incidence is extremely low — estimated at fewer than 1 per 1 million implanted animals.
The tumor concern originated primarily from the feline injection-site sarcoma literature, where a well-documented association exists between adjuvanted vaccine injections and fibrosarcoma development. Whether microchip-associated tumors follow the same inflammatory pathogenesis or represent coincidental findings at a common anatomical site remains debated.
Several key points contextualize the tumor risk:
- The absolute risk is orders of magnitude lower than the common causes of canine cancer
- The biological plausibility is uncertain — microchip glass is specifically selected for biocompatibility
- Reporting bias may inflate apparent incidence — tumors at microchip sites are more likely to be reported and published than tumors at other sites
- The incidence has not increased proportionally with the massive increase in microchip implantation, which would be expected if a strong causal relationship existed
MRI interference: Modern microchips can cause localized artifact on magnetic resonance imaging, potentially obscuring tissue in the immediate vicinity of the chip. Platt et al. (2006) noted this consideration for dogs requiring cervical or thoracic MRI. The artifact is limited to a small area around the chip and does not affect imaging of distant body regions.
Practical Recommendations
Based on the safety evidence:
- Microchipping remains recommended for all dogs. The reunion rate benefit substantially outweighs the extremely low adverse event risk.
- Have the microchip checked during annual veterinary visits to confirm it is scannable and document its location.
- Ensure registration information is current — Lord et al. (2009) found that outdated contact information was the primary reason microchipped dogs were not reunited with owners, not chip failure.
- If you notice a new mass at or near the microchip implantation site, have it evaluated veterinarily. While the overwhelming probability is that it is unrelated to the chip, histopathology can provide definitive characterization.
- For dogs scheduled for MRI of the cervical region, inform the radiologist of the microchip location so imaging protocols can be adjusted if needed.
Limitations
- Long-term safety data relies primarily on passive adverse event reporting, which underestimates true incidence
- No large prospective controlled studies compare health outcomes of microchipped versus non-microchipped populations
- Tumor association data is confounded by reporting bias and the difficulty of establishing causation for rare events
- New-generation microchips with temperature-sensing capability have a shorter safety track record
Related Science
Frequently Asked Questions
Can a microchip cause cancer in my dog?
Tumor formation at microchip sites has been documented but is rare — estimated at fewer than 1 per million implanted animals. The benefit of identification (52% reunion rate vs 22% without) substantially outweighs this minimal risk.
Do microchips ever fail?
Electronic failure is uncommon but documented. Chips can become unreadable due to manufacturing defects or, rarely, physical damage. Annual scanning during veterinary visits confirms functionality.
Does microchipping hurt?
The implantation needle is larger than a standard vaccination needle (approximately 12-gauge) and may cause brief discomfort. Most dogs show minimal reaction. No sedation or anesthesia is required.
Can a microchip be used to track my dog’s location?
No. Microchips are passive RFID devices with no GPS capability. They can only be read by a scanner held within a few inches of the chip. GPS tracking requires a separate collar-mounted device with a battery and cellular or satellite connectivity.
Bottom Line
Thirty years of microchip implantation data across tens of millions of animals demonstrates that the technology is safe with an extremely low adverse event rate. Migration is the most common issue and is clinically insignificant. Tumor formation, while documented, occurs at rates that are negligibly low compared to the identification and reunion benefits the technology provides.
References
- Vascellari M et al. Fibrosarcomas at presumed injection sites in dogs. J Vet Med A. 2003;50(6):286-291.
- Lord LK et al. Microchipped animals entering shelters. JAVMA. 2009;234(2):160-167.
- Swift S. Keeping pets safe: microchipping review. Companion Anim. 2019;24(7):376-381.